Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
GILD

Gilead

$73.76

0.34 (0.46%)

05:55
07/24/17
07/24
05:55
07/24/17
05:55
Hot Stocks
Gilead announces Phase 3 results for combination HIV-1 treatment »

Gilead Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Wednesday
GILD

Gilead

$71.69

0.54 (0.76%)

07:00
07/19/17
07/19
07:00
07/19/17
07:00
Hot Stocks
Gilead treatment of pediatric Crohn's disease granted FDA orphan status »

Gilead Sciences'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Tuesday
GILD

Gilead

$71.15

0.58 (0.82%)

13:37
07/18/17
07/18
13:37
07/18/17
13:37
Hot Stocks
Gilead reports FDA approval of Vosevi for re-treatment of chronic Hep C »

Gilead Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

GILD

Gilead

$71.15

0.58 (0.82%)

13:35
07/18/17
07/18
13:35
07/18/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Gilead »

Gilead reports FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

Over a week ago
VRTX

Vertex

$130.99

0.07 (0.05%)

, GILD

Gilead

$70.57

-0.01 (-0.01%)

11:22
07/15/17
07/15
11:22
07/15/17
11:22
Periodicals
Vertex, Gilead seen as innovators, Barron's says »

Jason Kritzer and…

VRTX

Vertex

$130.99

0.07 (0.05%)

GILD

Gilead

$70.57

-0.01 (-0.01%)

ZTS

Zoetis

$63.35

0.3 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 08

    Aug

INCY

Incyte

$133.42

0.2 (0.15%)

, GILD

Gilead

$70.58

0.78 (1.12%)

07:15
07/14/17
07/14
07:15
07/14/17
07:15
Recommendations
Incyte, Gilead analyst commentary at Leerink »

Acquisition of Incyte…

INCY

Incyte

$133.42

0.2 (0.15%)

GILD

Gilead

$70.58

0.78 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

GILD

Gilead

$69.80

0.45 (0.65%)

09:01
07/13/17
07/13
09:01
07/13/17
09:01
Recommendations
Gilead analyst commentary at Baird »

Baird likes Gilead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

GILD

Gilead

$69.80

0.45 (0.65%)

07:01
07/13/17
07/13
07:01
07/13/17
07:01
Hot Stocks
Gilead's marketing application for HIV infection treatment validated by EMA »

Gilead Sciences'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

GILD

Gilead

$69.29

0.04 (0.06%)

17:00
07/10/17
07/10
17:00
07/10/17
17:00
Initiation
Gilead initiated at Jefferies »

Gilead assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBPH

Spring Bank Pharmaceuticals

$15.14

-1.57 (-9.40%)

, GILD

Gilead

$69.25

-0.23 (-0.33%)

08:41
07/10/17
07/10
08:41
07/10/17
08:41
Hot Stocks
Spring Bank announces collaboration with Gilead for HBV Phase 2 study »

Spring Bank…

SBPH

Spring Bank Pharmaceuticals

$15.14

-1.57 (-9.40%)

GILD

Gilead

$69.25

-0.23 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.